Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old

Trial Profile

Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs TAK 003 (Primary)
  • Indications Dengue
  • Focus Registrational; Therapeutic Use
  • Acronyms TIDES
  • Sponsors Takeda
  • Most Recent Events

    • 05 Apr 2017 According to a Takeda media release, initial results are expected in 2018.
    • 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Sep 2016 According to a media release, first subject has been vaccinated in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top